Evidence map›Paper›PMID 32652470›Full record

ArticleTranslational oncology2020

CpG-coated prussian blue nanoparticles-based photothermal therapy combined with anti-CTLA-4 immune checkpoint blockade triggers a robust abscopal effect against neuroblastoma.

Juliana Cano-Mejia, Anshi Shukla, Debbie K Ledezma, Erica Palmer, Alejandro Villagra, Rohan Fernandes

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Nanoimmunotherapy: the smart trooper for cancer therapy.Exploration of targeted anti-tumor therapy · 2025
    Review
  9. Review
  10. Review
  11. Neuroblastoma-A Review of Combination Immunotherapy.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Article
  14. Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.International journal of molecular sciences · 2024
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Juliana Cano-MejiaThe George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA; Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Anshi ShuklaThe George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA.
Debbie K LedezmaFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA; The Institute for Biomedical Sciences, The George Washington University, Washington, DC 20037, USA.
Erica PalmerThe George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA.
Alejandro VillagraThe George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA.
Rohan FernandesThe George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA; The Institute for Biomedical Sciences, The George Washington University, Washington, DC 20037, USA; Department of Medicine, The George Washington University, Washington, DC 20037, USA. Electronic address: rfernandes@gwu.edu.
George Washington University · USUniversity of Maryland, College Park · US

Funding

Engineered Ensemble Nanoimmunotherapies for CancerR37CA226171 · NCI · GEORGE WASHINGTON UNIVERSITY · PI FERNANDES, ROHAN · 2019 to 2024
$2.6M
NCI NIH HHS R37 CA226171
6 · The paper itself

Abstract

High-risk neuroblastoma, which is associated with regional and systemic metastasis, is a leading cause of cancer-related mortality in children. Responding to this need for novel therapies for high-risk patients, we have developed a "nanoimmunotherapy," which combines photothermal therapy (PTT) using CpG oligodeoxynucleotide-coated Prussian blue nanoparticles (CpG-PBNPs) combined with anti-CTLA-4 (aCTLA-4) immunotherapy. Our in vitro studies demonstrate that in addition to causing ablative tumor cell death, our nanoimmunotherapy alters the surface levels of co-stimulatory, antigen-presenting, and co-inhibitory molecules on neuroblastoma tumor cells. When administered in a syngeneic, murine model of neuroblastoma bearing synchronous Neuro2a tumors, the CpG-PBNP-PTT plus aCTLA-4 nanoimmunotherapy elicits complete tumor regression in both primary (CpG-PBNP-PTT-treated) and secondary tumors, and long-term survival in a significantly higher proportion (55.5%) of treated-mice compared with the controls. Furthermore, the surviving, nanoimmunotherapy-treated animals reject Neuro2a rechallenge, suggesting that the therapy generates immunological memory. Additionally, the depletion of CD4

Indexed as

Abscopal effectCpG oligodeoxynucleotidesImmune checkpoint blockadeNanoimmunotherapyNeuroblastomaPrussian blue nanoparticles-based photothermal therapy

Identifiers

PMID32652470
PMCPMC7348061
OpenAlexW3041040828

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.